OverT Bio, an NYC-based cell therapy company, has been awarded a $120,000 G-Rex Grant from ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady. This grant will support OverT Bio’s ongoing development efforts, which will lead to next-generation cell therapies for solid tumors based on the data-driven discovery platforms OverTarget and OverTCR.
 
The G-Rex Grant is part of ScaleReady’s $20 million grant program aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing. The G-Rex Grant Program offers recipients significant no-cost support allowing for expeditious optimization of cell manufacturing processes.
 
“We are pleased to receive ScaleReady’s support and their recognition of the potentially high impact our technology has to advance our shared mission of bringing new life-saving therapeutics to cancer patients,” stated Mat Legut, PhD, CEO of OverT Bio. “This grant, including its access to newly developed GMP closed system products and ScaleReady’s expertise, will help us accelerate the development of our products in a way that will ensure future scalability and cost-effectiveness of these potential medicines.”
 
“Our support of OverT Bio is yet another example of how our G-Rex Grant Program is being used to facilitate advancement of the field of cell and gene-modified cell therapy,” said Josh Ludwig, Commercial Director of ScaleReady. “The G-Rex Grant Program augments ScaleReady’s primary purpose of providing every CGT company with the ability to save time and money while building a strong value proposition for continued investment on favorable terms.”